FIELD: pharmacology.
SUBSTANCE: invention refers to medicine and can be used as an effective remedy for precise delivery of DNA complexes with molecular conjugates to certain organs and tissues in mammals. The technical effect is ensured by introduction of modified nuclear localisation signal (NLS) that shall allow for conjugates to form complexes with plasmid DNA containing a suicidal gene, and also shall provide higher conjugate concentration in tumour cell nuclei that leads to intensification of cytotoxic properties of doxorubicine.
EFFECT: higher effectiveness of tumour cell exposure.
3 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODULE MOLECULAR CONJUGATE FOR TARGETING GENETIC CONSTRUCTS AND METHOD FOR PREPARING IT | 2012 |
|
RU2529034C2 |
| MOLECULAR CONJUGATES WITH POLYCATIONIC SECTION AND LIGAND FOR DELIVERY OF DNA AND RNA INTO CELL AND CELL NUCLEUS | 2009 |
|
RU2537262C2 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF | 2016 |
|
RU2722449C2 |
| DECAPEPTIDE SHOWING ANTITUMOR ACTIVITY | 1993 |
|
RU2084458C1 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| CONJUGATES OF DISORAZOL, BASED PHARMACEUTICAL COMPOSITIONS, SAID CONJUGATES FOR PREPARING DRUG, KIT AND METHOD FOR PREPARING THEM | 2007 |
|
RU2473562C2 |
| METHOD FOR PREVENTING ONSET OR REDUCING INCIDENCE OF ACUTE URINARY RETENTION | 2017 |
|
RU2721538C1 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| METHOD OF REDUCING SEVERITY OR PREVENTING ACERBATION OF PROGRESSION OF SYMPTOMS OF BPH | 2017 |
|
RU2744691C2 |
